Terms: = Breast cancer AND MUC16, CA125, CA-125 AND Treatment
133 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Potential Value of HSP90α in Prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
3. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract] [Full Text] [Related]
4. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.
Chi Y; Su M; Zhou D; Zheng F; Zhang B; Qiang L; Ren G; Song L; Bu B; Fang S; Yu B; Zhou J; Yu J; Li H
Elife; 2023 Nov; 12():. PubMed ID: 37929934
[TBL] [Abstract] [Full Text] [Related]
6. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
7. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
8. Development of Triple-Negative breast cancer-Targeted Liposomes with muc16 Binding Peptide Ligand in Triple-Negative breast cancer Cells.
Hagimori M; Kato N; Orimoto A; Suga T; Kawakami S
J Pharm Sci; 2023 Jun; 112(6):1740-1745. PubMed ID: 36878391
[TBL] [Abstract] [Full Text] [Related]
9. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
[No Abstract] [Full Text] [Related]
10. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
You B; Van Wagensveld L; Tod M; Sonke GS; Horlings HM; Kruitwagen RFPM; Du Bois A; Selle F; Perren T; Pfisterer J; Joly F; Cook A; Kaminsky MC; Wollschlaeger K; Lortholary A; Tome O; Leary A; Freyer G; Van Der Aa M; Colomban O
Br J Cancer; 2022 Jul; 127(1):79-83. PubMed ID: 35361918
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Multidisciplinary treatment Including Lenvatinib].
Furuya K; Ioka T; Shindo Y; Tokumitsu Y; Matsui H; Matsukuma S; Nakajima M; Yamada K; Watanabe Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Nagano H
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1694-1696. PubMed ID: 35046300
[TBL] [Abstract] [Full Text] [Related]
12. Application value of the treatment of breast cancer bone metastases with radioactive seed 125I implantation under CT-guidance.
Li H; Wang M; Zhu Z; Lu Y
BMC Med Imaging; 2022 Jan; 22(1):3. PubMed ID: 34983423
[TBL] [Abstract] [Full Text] [Related]
13. Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian cancer.
Li L; Chen F; Lin A; Wang D; Shi Y; Chen G
Comput Math Methods Med; 2021; 2021():4854282. PubMed ID: 34721658
[TBL] [Abstract] [Full Text] [Related]
14. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of breast cancer.
Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
[TBL] [Abstract] [Full Text] [Related]
15. The role of TPS, ca125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract] [Full Text] [Related]
16. Expression levels and clinical values of miR-92b-3p in breast cancer.
Du Y; Miao Z; Wang K; Lv Y; Qiu L; Guo L
World J Surg Oncol; 2021 Aug; 19(1):239. PubMed ID: 34380511
[TBL] [Abstract] [Full Text] [Related]
17. BARD1 Autoantibody Blood Test for Early Detection of Ovarian cancer.
Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
[TBL] [Abstract] [Full Text] [Related]
18. Chimeric Antigen Receptor Design and Efficacy in Ovarian cancer treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract] [Full Text] [Related]
19. Three phytosterols from sweet potato inhibit MCF7-xenograft-tumor growth through modulating gut microbiota homeostasis and SCFAs secretion.
Han B; Jiang P; Jiang L; Li X; Ye X
Food Res Int; 2021 Mar; 141():110147. PubMed ID: 33642013
[TBL] [Abstract] [Full Text] [Related]
20. A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?
Dellino M; Gargano G; Tinelli R; Carriero C; Minoia C; Tetania S; Silvestris E; Loizzi V; Paradiso A; Casamassima P; Tufaro A; Cormio G; Garrisi VM
Medicine (Baltimore); 2021 Feb; 100(5):e24485. PubMed ID: 33592901
[TBL] [Abstract] [Full Text] [Related]
[Next]
